About This Research
This NMSC Insights research consolidates U.S. GLP-1 supply status, price points and compounding policy as of 15 October 2026. It draws on FDA, Federal Register, CMS, CDC, BLS and TrumpRx.gov pages, SEC filings from Eli Lilly and Novo Nordisk, and KFF and association sources. Figures from trade press or telehealth pages are labelled secondary and are not treated as equivalent to primary data.
2026 Market Pulse Metrics
Price, payer and disease-burden reference points for the U.S. GLP-1 market, each traceable to a named source.
LOWEST BRANDED CASH PRICE
$149/mo
Wegovy pill, lowest tier, listed on TrumpRx.gov against a $1,349 list price.
ZEPBOUND VIAL CASH RANGE
$299–$449/mo
LillyDirect self-pay; the $449 price requires a refill within 45 days.
MEDICARE GLP-1 BRIDGE COPAY
$50/mo
1 Jul 2026 to 31 Dec 2027; CMS pays the balance of a $245 net price.
IRA NEGOTIATED PRICE (2027)
$274/mo
Ozempic, Wegovy and Rybelsus from 1 Jan 2027, against a $959 2024 list price.
U.S. ADULT OBESITY PREVALENCE
40.3%
CDC NHANES, Aug 2021 to Aug 2023; the latest measured national estimate.
ADULTS TAKING A GLP-1
12%
KFF poll, late 2025; 56% of users say the drugs are hard to afford.
Executive Summary: Supply Is No Longer the Constraint
Three forces now define the U.S. GLP-1 market, and they point the same way: supply has stopped being the bottleneck, prices paid by patients have fallen sharply, and the legal room for mass compounding has narrowed. NMSC’s framework for this tracker is simple: what a patient pays = list price − manufacturer cash discount − payer program, and what a compounder can sell = shortage status + FDA enforcement.
Supply. FDA declared the tirzepatide shortage resolved on 2 October 2024, reaffirmed on 19 December 2024, and the semaglutide shortage resolved on 21 February 2025. Liraglutide injection is the one GLP-1 ingredient still reported in shortage, according to a July 2026 docket comment. New oral options widen the supply base: Novo Nordisk’s Wegovy pill launched on 5 January 2026 and had passed 5 million U.S. prescriptions by 4 August, with weekly prescriptions above 265,000. Eli Lilly’s oral Foundayo (orforglipron) was approved on 1 April 2026.
Price. TrumpRx.gov lists the Wegovy pill from $149 a month against a $1,349 list price, Wegovy and Ozempic pens from $199, and the Zepbound vial from $299 against a $1,087 list price. Those cash prices sit 59% to 89% below list (NextMSC calculation). Novo will cut its list price for Wegovy, Ozempic and Rybelsus to $675 on 1 January 2027, the same day Medicare’s negotiated $274 price for semaglutide takes effect.
Compounding. After the shortage exceptions ended, FDA moved from warnings toward enforcement. On 30 April 2026 it proposed that semaglutide, tirzepatide and liraglutide not be added to the 503B bulks list. The comment period, extended once, closed on 30 July 2026, and no final determination appeared in the sources reviewed through mid-October.
NMSC Insight: the original economic case for compounding was a gap of roughly $1,000 a month between list prices and what a cash-paying patient could find elsewhere. With branded cash prices at $149 to $449, that gap has largely closed, which weakens the commercial pull toward unapproved products even before the legal pathway narrows further. This is a reading of sourced prices, not a clinical recommendation.
Why This Question Is Live in 2026
Three years of shortages, a wave of direct-to-patient pricing and a federal enforcement push have all landed within about eighteen months. The dated events below are the ones that moved prices or legal room.
2 October 2024 — FDA resolves the tirzepatide shortage
FDA declared the shortage of tirzepatide injection (Mounjaro, Zepbound) resolved and reaffirmed the decision on 19 December 2024 after reconsideration.
21 February 2025 — Semaglutide shortage resolved
FDA declared the semaglutide injection shortage over. Enforcement discretion for 503A pharmacies ran to 22 April 2025 and for 503B outsourcing facilities to 22 May 2025, according to an AmSpa summary of the FDA announcement.
November–December 2025 — Cash prices reset
Novo cut Wegovy and Ozempic cash prices from $499 to $349 in mid-November (trade press), and Lilly cut Zepbound vial prices on 1 December to $299, $399 and $449.
January–February 2026 — Pills and TrumpRx.gov
The Wegovy pill launched in the U.S. on 5 January 2026 from $149 a month. TrumpRx.gov went live on 6 February with manufacturer cash prices, and on 24 February Novo announced its 2027 list-price cut to $675.
1 April 2026 — Foundayo approved
FDA approved Lilly’s oral orforglipron for obesity on 1 April; it was available through LillyDirect from 6 April (trade press).
30 April–30 July 2026 — 503B bulks-list proposal
FDA proposed on 30 April, published in the Federal Register on 1 May, not to add semaglutide, tirzepatide or liraglutide to the 503B bulks list. The comment period was extended by 30 days and closed on 30 July.
1 July 2026 — Medicare GLP-1 Bridge begins
CMS’s demonstration lets eligible Part D members pay $50 a month for covered GLP-1 drugs through 31 December 2027.
2026 GLP-1 Price Index
There is no single GLP-1 price. A patient can face a list price, a cash price, a Medicare copay or a negotiated price, depending on how the drug is bought. The blocks below separate manufacturer, government and compounded-seller data.
BRANDED CASH PRICES: MANUFACTURER AND TRUMPRX
Branded cash — down 59% to 89% from list
$149
Wegovy pill, lowest tier (TrumpRx.gov)
$199
Wegovy / Ozempic pens, intro doses (TrumpRx.gov)
$299–$449
Zepbound vial range (LillyDirect)
Lilly’s lowest vial price applies to the 2.5 mg starter dose, which is not approved as a maintenance dose. The $449 price for 7.5 to 15 mg applies when the patient refills within 45 days; without that refill the regular price is $499 for 7.5 mg and $699 for 10, 12.5 and 15 mg (LillyDirect). Wegovy pen maintenance doses at $349 and higher Wegovy pill tiers at $299 come from secondary sources and should be confirmed on NovoCare.
PUBLIC PAYERS: CMS
Medicare — $50 today, $274 from 2027
$50
Bridge copay per month, from 1 Jul 2026
$245
Manufacturer net price under the Bridge
−71%
IRA price $274 vs $959 (2024 list)
Under the Bridge, CMS pays the balance after the $50 copay, about $195 (NextMSC calculation from the $245 net price). The $50 copay does not count toward the beneficiary’s true out-of-pocket threshold (CMS). The negotiated $274 price applies to the 30-day equivalent of Ozempic, Wegovy and Rybelsus from 1 January 2027.
COMPOUNDED SELLERS: UNAPPROVED, SECONDARY DATA
Compounded semaglutide — little price edge left
$149–$199
Monthly equivalent, 6-month prepaid plans (secondary)
$149
Wegovy pill, lowest branded cash tier
Not approved
FDA has not evaluated safety or effectiveness
Compounded prices are advertised by telehealth sellers and came from a competitor’s comparison blog, so they are indicative only. Seller pricing models changed during 2026 and legacy plans may have been withdrawn. They are not transaction prices.
Figure 1. Monthly Price by Channel, U.S. Dollars
USD per month. Blue = list price; amber = 2027 reset prices; green = patient-facing cash or copay; grey = Zepbound vial without the 45-day refill.
Source: Novo Nordisk, Eli Lilly, TrumpRx.gov, CMS and NextMSC analysis.
nextmsc.com/industry-deep-dive/glp-1-supply-pricing-compounding-2026
The ladder shows why cash buyers face a different market from insurers. A patient paying out of pocket for a Wegovy pill pays 11% of the list price, while the list price still sets the starting point for payer rebates and for the pharmacy-benefit economics behind them. Novo’s own 2027 reset to $675 is about 50% below the current Wegovy list price and, in Novo’s wording, approximately 35% below Ozempic’s; Novo says it does not change direct self-pay prices.
The Price Spectrum: Discount to List and Cost Over a Year
Two readings help a buyer compare channels: how far each cash price sits below its list price, and what staying on therapy costs across twelve months at that price.
Figure 2. Discount to List Price, Percent
Percent below list price = 1 − (price ÷ list). List prices: Wegovy $1,349, Ozempic $1,028, Zepbound $1,087, Medicare reference $959.
Source: TrumpRx.gov, Eli Lilly, CMS and NextMSC analysis.
nextmsc.com/industry-deep-dive/glp-1-supply-pricing-compounding-2026
Annualised cost of staying on therapy
The figures below multiply the monthly price by 12. They assume continuous use at that price and exclude telehealth membership fees and dose-escalation steps, so they are indicative of the price level, not a patient’s actual bill.
Figure 3. Annualised Cost at Monthly Price × 12, U.S. Dollars
USD per year, indicative. Wegovy pen maintenance is a secondary-source price.
Source: Eli Lilly, Novo Nordisk, CMS and NextMSC analysis.
nextmsc.com/industry-deep-dive/glp-1-supply-pricing-compounding-2026
The spread between a $600 Medicare year and a $5,388 top-tier Zepbound year is nearly nine-fold (NextMSC calculation). Channel, not just drug, is now the largest price variable.
The 4 Pillars of the GLP-1 Market in 2026
NMSC’s assessment looks past a single price to ask what drives it. Supply, price, payer and compounding together separate a headline price from one a patient can actually obtain and a seller can legally offer.
PILLAR 1
Supply — Shortages Have Ended, Competition Has Begun
FDA’s national shortage listings are resolved for the two blockbuster injectables, which matters legally as much as commercially: the shortage list is what allowed compounders to copy approved drugs. Oral formats add a second supply route. A pill avoids the cold-chain and injection-device steps that limited early supply, and the Wegovy pill’s run to more than 5 million prescriptions in seven months shows how fast a new format can scale.
Aggregate supply is not the same as a stocked shelf. FDA’s resolution means supply meets demand nationally, not that every pharmacy always holds every dose. Lilly’s management said about 45% of Zepbound prescriptions, and 55% of new ones, were self-pay in Q2 2026 (earnings-call transcript, secondary), which shows how large the direct-to-patient channel has become.
PILLAR 2
Price — Manufacturers Now Compete on Cash
Cash pricing has moved from an experiment to the main competitive weapon. Lilly’s Zepbound vial launched in August 2024 at $399 for 2.5 mg and $549 for 5 mg per four-week supply, and by December 2025 it was $299 and $399. Novo’s pens fell from $499 to $349, with $199 introductory doses, and the Wegovy pill opened at $149.
The financial effect is visible in the results. Lilly reported Q2 2026 revenue of $23.0 billion, up 48%, with Mounjaro at $9.94 billion and Zepbound at $4.93 billion, and noted lower realised prices from its cash-price cuts. Volume growth is offsetting price, at least for now. Novo reported Q2 2026 adjusted sales growth of 7% at constant exchange rates against 3% reported, reflecting a 340B base effect.
PILLAR 3
Payer — Medicare Sets the Floor and the Next Cliff
Medicare is the largest public-payer lever. Part D gross spending on GLP-1s reached $27.5 billion in 2024, about five times the 2019 level, and KFF estimates roughly $14 billion net if rebates run near 50%, which is an estimate rather than a reported figure. About 2 million Part D enrollees used Ozempic and nearly 1 million used Mounjaro that year.
The Bridge brings obesity coverage in through a demonstration at $50 a month, and KFF estimates about 3.8 million beneficiaries met its criteria in 2023 data. The structural cliff is the end date: the Bridge ends on 31 December 2027, and the sources reviewed do not settle what replaces it. That uncertainty matters to health insurance planners and to patients who would otherwise face list-linked pricing again.
PILLAR 4
Compounding — From Shortage Exception to Enforcement Target
While semaglutide and tirzepatide were on FDA’s shortage list, compounders could prepare copies of the branded drugs and telehealth firms sold them to cash-paying patients. Once the shortages ended, the legal basis for making essentially a copy ended with them. FDA’s 30 April 2026 proposal would make the exclusion of semaglutide, tirzepatide and liraglutide from the 503B bulks list formal.
What remains is narrow. FDA states that semaglutide and tirzepatide are on neither the 503B bulks list nor the shortage list. Patient-specific compounding by 503A pharmacies is not removed by the bulks-list proposal, but FDA says compounded drugs should be used only for patients whose needs an approved drug cannot meet. FDA also states that semaglutide salt forms (sodium, acetate) are different active ingredients from those in approved drugs and that investigational drugs such as retatrutide cannot be compounded.
Product, Price and Status Matrix
Price, supply status and regulatory exposure are separate dimensions. The matrix sets the main products against each other on the sourced indicators. It is an analytical framework, not a ranking, and secondary rows are labelled.
| Product | Lowest cash price | List reference | Supply / approval status | Channel note |
|---|---|---|---|---|
| Wegovy pill (oral semaglutide 25 mg) | $149/mo (TrumpRx.gov) | $1,349 | Approved Dec 2025; launched 5 Jan 2026 | Higher tiers reported at $299 (secondary) |
| Wegovy pen (semaglutide injection) | $199 intro; $349 maintenance (secondary) | $1,349 | Shortage resolved 21 Feb 2025 | List falls to $675 from 1 Jan 2027 |
| Wegovy HD (semaglutide 7.2 mg) | $399/mo (secondary) | n/a | U.S. launch Apr 2026 | Price from a telehealth listing |
| Ozempic (semaglutide, type 2 diabetes) | $199 intro (TrumpRx.gov) | $1,028 | Shortage resolved 21 Feb 2025 | Medicare negotiated $274 from 2027 |
| Zepbound vial (tirzepatide) | $299 / $399 / $449 | $1,087 | Shortage resolved 2 Oct 2024 | 45-day refill needed for $449 |
| Foundayo (orforglipron pill) | $149 starting dose (secondary) | n/a | Approved 1 Apr 2026 | $25 with commercial savings card (secondary) |
| Liraglutide (Victoza, Saxenda, generics) | Not tracked | n/a | Reported in shortage, Jul–Aug 2026 (secondary) | Named in the 503B proposal |
Product-Level Case Studies
Rather than cover every SKU, NMSC picks six contrasting cases to show how price, supply and policy interact. The full records are in the Dataset Explorer below.
Wegovy pill
ORAL FORMAT + LOWEST CASH ENTRY
Novo launched the pill on 5 January 2026 and TrumpRx.gov lists it from $149 a month against a $1,349 list price, an 89% discount (NextMSC calculation). Novo reports more than 5 million U.S. prescriptions since launch and weekly prescriptions above 265,000 in the week ending 17 July. One telehealth-review page reports $299 for the 9 mg and 25 mg tiers, which should be confirmed on NovoCare before quoting.
Zepbound vials
TIERED CASH PRICING + A REFILL CONDITION
LillyDirect sells single-dose vials at $299 for 2.5 mg, $399 for 5 mg and $449 for 7.5 to 15 mg with a refill inside 45 days. Without the refill the 7.5 mg price is $499 and the 10, 12.5 and 15 mg price is $699, so the headline $449 depends on adherence to the refill window. Zepbound revenue was $4.93 billion in Q2 2026, which Lilly said grew despite lower realised prices.
Medicare GLP-1 Bridge
PUBLIC PAYER + TIME-LIMITED
From 1 July 2026 to 31 December 2027, eligible Part D beneficiaries pay $50 a month and manufacturers supply at a $245 net price, leaving about $195 for CMS. The copay does not count toward the true out-of-pocket threshold. From 1 January 2027 the negotiated $274 price for Ozempic, Wegovy and Rybelsus also applies, a 71% cut from the 2024 list price of $959.
Novo’s 2027 list-price reset
LIST VS NET
Announced on 24 February 2026, the cut takes the Wegovy and Ozempic list prices to $675 from 1 January 2027, about 50% below Wegovy’s current list and approximately 35% below Ozempic’s (Novo’s wording; our arithmetic on $1,028 gives 34%). Novo said it does not change self-pay prices, so the effect lands on payers and on the list-based price points that rebates are measured against.
Compounded semaglutide
LEGAL ROOM NARROWING + SMALL PRICE EDGE
Compounded injections were advertised at roughly $149 to $199 a month equivalent on 6-month plans in competitor-reported pages, against $149 for the branded pill. On 5 February 2026 Hims & Hers announced a $49 first-month compounded semaglutide pill that was withdrawn within days, as described in Hims’ own announcement and press coverage. FDA’s stance is that these products are unapproved and have not been evaluated for safety or effectiveness.
Liraglutide
THE ONE REMAINING SHORTAGE
A July 2026 comment letter from the Partnership for Safe Medicines states that liraglutide remains in shortage, and a secondary tracker reported the same in August. Liraglutide is also named in FDA’s 503B proposal. Because this status comes from secondary sources, it should be confirmed on FDA’s Drug Shortages Database before it is quoted as current.
What to Watch: Supply, Price and Policy Action Matrix
The next ninety days turn on a short list of dated events. The matrix pairs each with who is exposed and what to check.
| Event | Timing | Who is exposed | What to check |
|---|---|---|---|
| FDA final determination on the 503B bulks list | Comment period closed 30 Jul 2026; no timeline announced | Compounders, telehealth sellers | Federal Register for a final notice |
| Novo $675 list price and Medicare $274 price | 1 Jan 2027 | Payers, PBMs, Part D plans | Rebate terms and formulary updates |
| Medicare Bridge end | 31 Dec 2027 | ~3.8M eligible beneficiaries (KFF estimate) | CMS statements on any successor path |
| Retatrutide filing | Q1 2027 (Lilly plan) | Lilly, competitors | FDA cannot compound investigational drugs |
| Liraglutide shortage status | Ongoing | Hospitals, pharmacies | FDA Drug Shortages Database |
| Cash-price promotions | Rolling; some end dates reported inconsistently | Cash-pay patients | TrumpRx.gov, LillyDirect, NovoCare on the day |
Methodology and Data Limitations
This analysis compares U.S. GLP-1 prices, supply status and compounding policy as of 15 October 2026. The aim is to show where prices differ by channel and what the legal position is, not to forecast prices or advise on treatment.
Methodology
- Regulatory status comes from FDA and Federal Register pages, CMS pages and, where stated, association or trade-press summaries of FDA announcements.
- Prices come from TrumpRx.gov, LillyDirect and Novo Nordisk, with higher-uncertainty prices from telehealth, aggregator and trade-press pages labelled secondary in the text and in the dataset.
- Macro indicators come from CDC, BLS, KFF, SEC filings and Novo Nordisk’s results release.
- Discounts are calculated as 1 − (price ÷ list) and annualised costs as monthly price × 12. Each is a NextMSC calculation on the cited inputs.
Data Limitations
- Prices change often through manufacturer promotions, dose tiers and refill conditions, so re-check manufacturer and TrumpRx.gov pages on the day of use.
- Compounded prices are sellers’ advertised prices for unapproved products, not verified transactions.
- CDC obesity prevalence pre-dates the 2024–26 uptake of GLP-1s, and the KFF usage figure is a survey self-report from late 2025.
- Rows from trade press, law firms and telehealth pages are labelled secondary or unverified in the dataset; items that could not be confirmed on a primary page are not stated as fact in the text.
- This is market analysis, not medical advice or guidance on whether to use any medicine.
Source: FDA, Federal Register, CMS, CDC, BLS, KFF and company filings and NextMSC analysis.
nextmsc.com/industry-deep-dive/glp-1-supply-pricing-compounding-2026
Key Findings
Supply is resolved for the big two
FDA resolved the tirzepatide shortage on 2 October 2024 and the semaglutide shortage on 21 February 2025; liraglutide is the one ingredient reported in shortage.
Cash prices are 59% to 89% below list
The Wegovy pill at $149 sits 89% below a $1,349 list price and the Zepbound vial range of $299 to $449 sits 59% to 72% below $1,087 (NextMSC calculation).
Channel now matters more than drug
A Medicare Bridge year costs $600 at $50 a month, against $5,388 for top-tier Zepbound vials with refill, a nearly nine-fold spread.
January 2027 is a price pivot
Novo’s $675 list price and Medicare’s $274 negotiated price both take effect on 1 January 2027.
Compounding’s price edge has shrunk
Compounded semaglutide at about $149 to $199 a month equivalent is close to the $149 branded pill, while FDA’s proposal narrows the bulk-compounding route.
Medicare’s path after 2027 is open
The Bridge ends on 31 December 2027 and the sources reviewed do not say what follows.
Dataset Explorer
Filter the full 88-record dataset compiled for this report: prices, price events, macro indicators, supply status and the compounding timeline. Rows that rest on trade press, law-firm notes or unconfirmed claims are tagged in the item text.
| Category | Item | Value / Change | Date |
|---|
Need Custom Data?
Our analysts can extract and normalize custom reports for your specific drug, channel or geography.
Speak to an AnalystConclusion
The U.S. GLP-1 market in October 2026 looks very different from the shortage-driven market of 2023 to 2024. Supply is no longer the constraint for semaglutide and tirzepatide, direct-to-patient cash prices have fallen to between $149 and $449 a month against list prices above $1,000, and Medicare has a $50 route for eligible members through 2027. The question for a buyer or planner has shifted from whether a drug can be found to which channel it is bought through.
Compounding has moved from a shortage-era exception to an enforcement target, and the cost advantage that once justified it has narrowed to a few dozen dollars a month on the secondary price data available. The open items are dated and checkable: FDA’s final bulks-list determination, the 1 January 2027 list and negotiated price changes, and what replaces the Medicare Bridge after 2027. NextMSC’s framework of list price, cash discount, payer programme and enforcement status is a starting point for that view, not a forecast. This tracker will be refreshed monthly.
About the Author
Liza Phukan
— Liza Phukan is Research Associate at Next Move Strategy Consulting, where she has covered emerging industries and market research across sectors for 3.5 years. Her work includes analyzing industry developments, validating market data, and developing structured business content from research findings. She uses secondary research and data-validation practices to turn complex market information into clear decision-useful market analysis for business audiences and support report development and B2B.
About the Reviewer
Debashree Dey
— Debashree Dey is Assistant Manager at Next Move Strategy Consulting, where she supports cross-vertical market content and communications across diverse industries for 6 years. Her professional background includes senior content writing, communications, and published manuscript authorship, with experience developing audience-focused business narratives and maintaining clear, consistent messaging. Her role supports research-led content development and editorial quality across NextMSC publications.
Data cut-off: October 15, 2026 • Corrections and source challenges: Contact NMSC Research.